SCHEMBL4943779

SCHEMBL4943779

COc1ccccc1CNC(=O)CCc1nnc(SCc2cc(C)cc(C)c2)n1-c1cccc(Cl)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TP53 P04637 2/20 0.47
CYP1A2 P05177 1/20 0.44
CYP3A4 P08684 1/20 0.44
CYP2D6 P10635 1/20 0.44
CYP2C9 P11712 1/20 0.44
CYP2C19 P33261 1/20 0.44
ALDH1A1 P00352 6/20 0.44
NPSR1 Q6W5P4 4/20 0.44
MAPT P10636 2/20 0.44
ANO1 Q5XXA6 1/20 0.43
ANO2 Q9NQ90 1/20 0.43
HPGD P15428 2/20 0.42
THRB P10828 2/20 0.42
GLA P06280 1/20 0.42
LMNA P02545 1/20 0.42
KDM4E B2RXH2 2/20 0.42
TSHR P16473 1/20 0.42
RECQL P46063 1/20 0.42
HTT P42858 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4945498 0.95 TP53 (0.50) TP53CYP1A2CYP3A4CYP2D6CYP2C9
SCHEMBL4942571 0.93 ALDH1A1 (0.46) CYP2D6CYP2C19ALDH1A1NPSR1MAPT
SCHEMBL4945531 0.93 TP53 (0.51) TP53CYP1A2CYP3A4CYP2D6CYP2C9
SCHEMBL4937997 0.92 TP53 (0.51) TP53CYP1A2CYP3A4CYP2D6CYP2C9
SCHEMBL4944216 0.91 TP53 (0.47) TP53CYP1A2CYP3A4CYP2D6CYP2C9
SCHEMBL4937715 0.90 ALDH1A1 (0.53) TP53CYP1A2CYP3A4CYP2D6CYP2C9
SCHEMBL4942023 0.88 HPGD (0.48) CYP2D6CYP2C19ALDH1A1NPSR1MAPT
SCHEMBL4945459 0.88 TP53 (0.53) TP53CYP1A2CYP3A4CYP2D6CYP2C9
SCHEMBL4944445 0.88 HPGD (0.51) TP53CYP1A2CYP3A4CYP2D6CYP2C9
SCHEMBL4944071 0.88 TP53 (0.52) TP53CYP1A2CYP3A4CYP2D6CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7468385-B2 Triazoles as oxytocin antagonists LABORATOIRES SERONO SA (CH) 2008-12-23 US claimed
EP-1458381-B1 TRIAZOLES AS OXYTOCIN ANTAGONISTS APPLIED RESEARCH SYSTEMS (AN) 2005-11-30 EP claimed
US-20050187275-A1 Triazoles as oxytocin antagonists APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) 2005-08-25 US claimed
EP-1458381-A1 TRIAZOLES AS OXYTOCIN ANTAGONISTS Applied Research Systems ARS Holding N.V. (AN) 2004-09-22 EP claimed
WO-2003053437-A1 TRIAZOLES AS OXYTOCIN ANTAGONISTS APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) 2003-07-03 WO claimed
US-7468385-B2 Triazoles as oxytocin antagonists LABORATOIRES SERONO SA (CH) 2008-12-23 US disclosed
US-7468385-B2 Triazoles as oxytocin antagonists LABORATOIRES SERONO SA (CH) 2008-12-23 US disclosed
US-7468385-B2 Triazoles as oxytocin antagonists LABORATOIRES SERONO SA (CH) 2008-12-23 US disclosed
US-20050187275-A1 Triazoles as oxytocin antagonists APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) 2005-08-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050187275-A1 Triazoles as oxytocin antagonists OXTR, AVPR2, AVPR1B TP53 4351/4885CYP1A2 1042/4885CYP3A4 2195/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.